

Extended Abstract

Mechanisms of Inhibitory Effects of Polysubstituted Pyrimidines on Prostaglandin E₂ Production †

Zdeněk Zídek ^{1,*}, Viktor Kolman ², Ondřej Baszczyński ², Filip Kalčic ², Daniel Board ² and Zlatko Janeba ²

¹ Institute of Experimental Medicine, The Czech Academy of Sciences, 142 20 Prague, Czech Republic

² Institute of Organic Chemistry and Biochemistry, The Czech Academy of Sciences, 166 10 Prague, Czech Republic

* Correspondence: zdenek.zidek@iem.cas.cz

† Presented at the 2nd Molecules Medicinal Chemistry Symposium (MMCS): Facing Novel Challenges in Drug Discovery, Barcelona, Spain, 15–17 May 2019.

Received: 7 August 2019

Keywords: pyrimidine analogues; prostaglandin E₂; prostaglandin E₂ synthase-1 inhibitors; anti-inflammatory activity

The pyrimidine heterocycle represents an elemental structural motif of numerous drugs. We have synthesized a large series of original derivatives possessing different substituents at C-2, C-4, C-5, and C-6 positions of the pyrimidine ring. The vast majority of prepared pyrimidines inhibit prostaglandin E₂ (PGE₂) production as revealed in vitro in the lipopolysaccharide (LPS)-stimulated mouse macrophages [1,2]. A number of them are effective at sub-micromolar concentration. The compounds are devoid of cytotoxic effects. They do not inhibit activities of phospholipase A2 (sPLA2), cyclooxygenases COX-1 and COX-2, and important enzymes in the PGE₂ biosynthesis pathway. A plausible explanation for the mechanism of PGE₂-inhibitory effects of pyrimidines is provided by findings showing substantial inhibition of activity of the terminal enzyme in PGE₂ formation, i.e., microsomal prostaglandin E₂ synthase-1 (mPGES-1). The IC₅₀s characterizing the potential of compounds to reduce mPGES-1 activity on one site and LPS-induced PGE₂ production on the other one are statistically significantly correlated.

Pyrimidine derivatives exhibit anti-inflammatory activity in vivo, as demonstrated by the significant reduction of carrageenan-induced paw oedema in rats. The findings suggest that pyrimidine inhibitors of mPGES-1 activity and consequent PGE₂ production may be considered as promising candidates for further preclinical research and development of novel non-steroidal anti-inflammatory drugs.

Acknowledgments: The research was supported by grant TE01020028 from the Technology Agency of the Czech Republic.

References

- 1 Zídek, Z.; Kverka, M.; Dusilová, A.; Kmoníčková, E.; Jansa, P. Dual inhibition of nitric oxide and prostaglandin E₂ production by polysubstituted 2-aminopyrimidines. *Nitric Oxide* **2016**, *57*, 48–56.
- 2 Kolman, V.; Kalčic, F.; Jansa, P.; Zídek, Z.; Janeba, Z. Influence of the C-5 substitution in polysubstituted pyrimidines on inhibition of prostaglandin E₂ production. *Eur. J. Med. Chem.* **2018**, *156*, 295–301.



© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).